Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence?

Several recent randomized controlled trials (RCTs) have demonstrated the wide clinical application of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in improving kidney and cardiovascular outcomes in patients with native kidney disease. In April 2021, Dapagliflozin became the first SGLT2 inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ujjawal, Aditi, Schreiber, Brittany, Verma, Ashish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Diabetic Kidney Disease: Pathogenesis and Therapeutic Targets
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016587/
https://www.ncbi.nlm.nih.gov/pubmed/35450095
http://dx.doi.org/10.1177/20420188221090001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016587/
https://www.ncbi.nlm.nih.gov/pubmed/35450095
http://dx.doi.org/10.1177/20420188221090001

Ejemplares similares